AR106330A1 - Formulaciones de corticoesteroide para mantener las concentraciones de corticoesteroide en líquido sinovial - Google Patents

Formulaciones de corticoesteroide para mantener las concentraciones de corticoesteroide en líquido sinovial

Info

Publication number
AR106330A1
AR106330A1 ARP160103120A ARP160103120A AR106330A1 AR 106330 A1 AR106330 A1 AR 106330A1 AR P160103120 A ARP160103120 A AR P160103120A AR P160103120 A ARP160103120 A AR P160103120A AR 106330 A1 AR106330 A1 AR 106330A1
Authority
AR
Argentina
Prior art keywords
formulations
corticoesteroid
release
extended
corticosteroid
Prior art date
Application number
ARP160103120A
Other languages
English (en)
Inventor
Williamson Toni
Jackson Derek
Bodick Neil
Original Assignee
Flexion Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Flexion Therapeutics Inc filed Critical Flexion Therapeutics Inc
Publication of AR106330A1 publication Critical patent/AR106330A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)

Abstract

Composiciones y métodos para lograr y mantener un máximo efecto analgésico luego de la administración intra-articular de formulaciones de corticoesteroides. Formulaciones de liberación extendida, por ejemplo, formulaciones de corticoesteroides de liberación controlada o sostenida, que incluyen formulaciones de liberación extendida, por ejemplo, formulaciones de liberación controlada o sostenida de triamcinolona acetonida (TCA, por sus siglas en inglés), propionato de fluticasona, cortisol, ciclesonida (monopropionato), dipropionato de beclometasona, dexametasona, flunisolida, budesonida, desisobutiril-ciclesonida y/o furoato de mometasona, que producen un máximo efecto analgésico superior al efecto agudo analgésico provisto por las suspensiones de corticoesteroide estándar, incluyendo las suspensiones de corticoesteroide de liberación no extendida y que también están asociadas con un efecto clínicamente insignificante sobre la producción de cortisol endógeno luego de la administración intra-articular, intratecal, epidural, intrabursal u otro tipo de administración local.
ARP160103120A 2015-10-13 2016-10-13 Formulaciones de corticoesteroide para mantener las concentraciones de corticoesteroide en líquido sinovial AR106330A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562240811P 2015-10-13 2015-10-13

Publications (1)

Publication Number Publication Date
AR106330A1 true AR106330A1 (es) 2018-01-03

Family

ID=58498560

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160103120A AR106330A1 (es) 2015-10-13 2016-10-13 Formulaciones de corticoesteroide para mantener las concentraciones de corticoesteroide en líquido sinovial

Country Status (5)

Country Link
US (1) US20170100411A1 (es)
AR (1) AR106330A1 (es)
TW (1) TW201726145A (es)
UY (1) UY36948A (es)
WO (1) WO2017066423A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023086550A1 (en) * 2021-11-11 2023-05-19 Academia Sinica Methods of diagnosing and treating osteoarthritis
US11896719B2 (en) 2022-01-24 2024-02-13 Calliditas Therapeutics Ab Pharmaceutical compositions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA111162C2 (uk) * 2010-08-04 2016-04-11 Флекшен Терап'Ютікс, Інк. Ін'єкційна композиція ацетоніду триамцинолону для лікування болю
WO2014153384A1 (en) * 2013-03-19 2014-09-25 Flexion Therapeutics, Inc. Corticosteroid formulations for the treatment of joint pain and methods of use thereof
WO2014153541A1 (en) * 2013-03-21 2014-09-25 Eupraxia Pharmaceuticals USA LLC Injectable sustained release composition and method of using the same for treating inflammation in joints and pain associated therewith

Also Published As

Publication number Publication date
TW201726145A (zh) 2017-08-01
WO2017066423A1 (en) 2017-04-20
US20170100411A1 (en) 2017-04-13
UY36948A (es) 2017-05-31

Similar Documents

Publication Publication Date Title
MX2018014978A (es) Composiciones nasales de cannabidiol.
BR112014027681B8 (pt) Nanocristais de propionato de fluticasona, composição tópica farmacêutica compreendendo os mesmos, seu uso e método de fabricação
MX2018006800A (es) Composicion farmaceutica.
BR112015023629A8 (pt) Formulação de acetato de abiraterona
CO2017003396A2 (es) Esteroides neuroactivos, composiciones y usos de los mismos
CL2019001447A1 (es) Preparación de complejos sólidos de ciclodextrina para suministro de ingredientes farmacéuticos activos oftálmicos.
BR122021018243A8 (pt) Composição tópica de baixo ph e método para aumentar a aplicação tópica de um ingrediente ativo cosmeticamente aceitável
EA201691808A1 (ru) Кортикостероидные композиции для местного применения
TR201817995T4 (tr) Nöroakti̇f steroi̇dler ve kullanim yöntemleri̇
UY36741A (es) Compuesto de esteroide c-20, sus composiciones y usos para tratar la lesión cerebral traumática (tbi), que incluye las conmociones cerebrales
CO2017002472A2 (es) Formulación de acetato de abiraterona
MX2017015879A (es) Composiciones de hidroxipropil beta-ciclodextrina y metodos.
CL2019001092A1 (es) Tratamientos de combinación que comprenden la administración de imidazopirazinonas.
AR097078A1 (es) Combinaciones que comprenden compuestos maba y corticosteroides, uso, kit y compuesto
CL2017001073A1 (es) 2,4 diamino-quinolia sustituido como nuevos agentes anticancerigenos
CR20160394A (es) Heteroaril amidas como inhibidores de agregación de proteína
BR112016003584A8 (pt) composições farmaceuticas e uso das mesmas para regressão de placa acelerada
FR3058059B1 (fr) Composition pharmaceutique comprenant le beta-elemene, le lupeol et le 2-hydroxycinnamaldehyde et/ou le 2'-benzoyloxycinnalmaldehyde et/ou le beta-sitosterol et/ou la curcumine.
DOP2015000005A (es) Derivados de estra 1,3,5(10), 16 tetraeno 3 sustituidos, métodos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos
BR112018007635A2 (pt) ?composição cosmética?
AR106330A1 (es) Formulaciones de corticoesteroide para mantener las concentraciones de corticoesteroide en líquido sinovial
AR106687A1 (es) PROCESO PARA PREPARAR UNA FORMULACIÓN EN POLVO SECO QUE COMPRENDE UN ANTICOLINÉRGICO, UN CORTICOSTEROIDE Y UN b-ADRENÉRGICO
MX2018006799A (es) Composicion farmaceutica.
AR123674A2 (es) Composición farmacéutica en aerosol de formoterol y dipropionato de beclometasona
ECSP19016844A (es) Combinación de agonistas de fxr

Legal Events

Date Code Title Description
FB Suspension of granting procedure